Core Insights - Eli Lilly has entered a $2.75 billion agreement with Insilico Medicine to commercialize AI-developed drugs [1] - Insilico has created at least 28 drugs using generative AI, with nearly half in clinical stages [2] - The collaboration aims to enhance drug discovery and development processes [4] Group 1: Financial Aspects - Insilico will receive $115 million upfront, with additional payments tied to regulatory and commercial milestones, plus royalties on future sales [1] - Eli Lilly plans to invest $3 billion in China over the next decade, with less than 3% of its revenue coming from China last year [5] Group 2: Technological Collaboration - Insilico will join Lilly's Gateway Labs community for biotech development as part of the agreement [3] - The partnership is expected to leverage Insilico's AI capabilities to identify promising therapeutic candidates across various disease areas [4] Group 3: Market Performance - Insilico's shares have increased by over 50% year-to-date since going public in Hong Kong in December [2]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 77.70 and a fair value of HKD 108.28 [3]. Core Insights - The company reported a strong performance in H2 2025, with revenue of RMB 2.65 billion, a year-on-year increase of 63%, and a net profit attributable to shareholders of RMB 300 million, up 85% year-on-year [7]. - For the full year of 2025, the company achieved revenue of RMB 4.47 billion, representing a 36% year-on-year growth, and a net profit of RMB 500 million, up 52% year-on-year [7]. - The company is expected to benefit from the takeout delivery boom, with management's e-commerce background enhancing user acquisition and retention capabilities [7]. - The company has been expanding its store network rapidly, adding 2,271 franchise stores in 2025, reaching a total of 11,423 stores [7]. - The main brand is expected to maintain resilience in same-store sales growth, supported by product innovation and expansion into new categories [7]. - The adjusted net profit forecast for 2026-2028 is RMB 6.7 billion, RMB 7.8 billion, and RMB 9.0 billion, respectively [7]. Financial Projections - The company’s main revenue is projected to grow from RMB 3.29 billion in 2024 to RMB 6.95 billion in 2028, with growth rates of -1.9%, 36.0%, 17.8%, 16.1%, and 13.8% respectively [2]. - Non-GAAP net profit is expected to increase from RMB 418 million in 2024 to RMB 897 million in 2028, with growth rates of 36.4%, 17.2%, 17.2%, and 14.6% [2]. - The Non-GAAP EPS is projected to rise from RMB 4.08 in 2024 to RMB 8.53 in 2028 [2]. - The company is expected to maintain a strong return on equity (ROE) of around 27.2% by 2028 [2].

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 滬上阿姨（上海）實業股份有限公司 | | | 股份代號 | 02589 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截止2025年12月31日止之末期股息 | | 公告日期 | 2026年3月24日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 10 股 10 RMB | | 股東批准日期 | 2026年6月24日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Auntea Jenny (Shanghai) Industrial Co., Ltd. 滬上阿姨（上海）實業股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：02589） 截 至2025年12月31日止年度之年度業績公告 滬上阿姨（上 海）實業股份有限公司（「本公司」）董 事（「董 事」）會（「董事會」）僅此宣佈本 公司及其附屬公司（統 稱「本集團」）截 至2025年12月31日止年度（「報告期」）之綜合年 度 業 績，連 同2024年 同 期 的 比 較 數 字 如 下： 財務表現摘要 | 至12月31日止年度 | 截 | 2025年 | 2024年 | 變動 | | | | | | | | | | | --- | --- ...

Group 1: Strategy Insights - The financial system's fragility is expected to drive monetary easing in leading countries, with 2026 likely witnessing a bull market in commodities alongside a manufacturing leap by catching-up nations like China [1][9] - In the first half of 2026, it is recommended to increase allocation to the PPI chain, particularly in oil and chemicals, while also focusing on Chinese manufacturing sectors such as photovoltaics, wind power, energy storage, and construction machinery [1][9] - The second half of 2026 should shift focus to the CPI chain, particularly in the liquor sector, and also consider investments in Hang Seng Technology and gold, which are expected to benefit from a rebound in the US dollar index [1][9] Group 2: Company Analysis - Hu Shang A Yi (沪上阿姨) - Hu Shang A Yi has a diversified brand matrix that covers various categories and price ranges, allowing it to fully benefit from growth in different market segments [2][13] - The company is focusing on deepening its presence in lower-tier markets and small store formats, which provides a competitive advantage [2][13] - Revenue projections for Hu Shang A Yi are estimated at 4.197 billion, 4.894 billion, and 5.790 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 493 million, 556 million, and 667 million yuan [2][13] Group 3: Company Analysis - Hai Tong Development (海通发展) - Hai Tong Development reported a revenue of 4.443 billion yuan for 2025, reflecting a year-on-year increase of 21.43% [3][21] - The company achieved a foreign trade revenue of 2.899 billion yuan, up 21.87% year-on-year, while domestic revenue reached 1.205 billion yuan, increasing by 27.78% [3][21] - The overall gross margin slightly declined to 16.29%, down 1.87 percentage points year-on-year, primarily due to a decrease in the gross margin of foreign trade business [3][22] Group 4: Company Analysis - Fangda Special Steel (方大特钢) - Fangda Special Steel achieved a revenue of 18.233 billion yuan in 2025, a decrease of 15.43% year-on-year, while net profit surged by 280.18% to 942 million yuan [25][26] - The company optimized its product structure, resulting in improved profitability metrics, with a gross margin of 9.65%, up 4.85 percentage points year-on-year [25][26] - The production and sales of high-margin products like spring flat steel and automotive leaf springs increased, indicating a successful shift in product strategy [25][26] Group 5: Company Analysis - Xiangcai Co., Ltd. (湘财股份) - Xiangcai Co., Ltd. reported a total revenue of 2.420 billion yuan and a net profit of 464 million yuan for 2025, reflecting increases of 10.37% and 325.15% respectively [29][30] - The company experienced significant growth in its commission income, which rose by 40.11% year-on-year, driven by an active market [29][30] - The firm is focusing on enhancing its self-operated investment performance, which saw a 9.36% increase in investment income [29][30] Group 6: Company Analysis - Chery Automobile (奇瑞汽车) - Chery Automobile achieved a revenue of 300.29 billion yuan in 2025, marking an 11.3% increase year-on-year, with a net profit of 19.02 billion yuan, up 34.6% [33][34] - The company reported a significant increase in overseas sales, with exports reaching 1.294 million units, a growth of 33.2% [33][34] - Chery's strategy includes a multi-brand approach, with plans to launch 16 new models over the next three years, enhancing its market presence [33][35] Group 7: Company Analysis - China Jushi (中国巨石) - China Jushi reported a revenue of 18.881 billion yuan for the first three quarters of 2025, a year-on-year increase of 19.08%, with a net profit of 3.285 billion yuan, up 34.38% [37][38] - The company is focusing on high-end markets, with electronic fabric sales increasing by 21.4% year-on-year, driven by demand from the information technology sector [37][38] - The gross margin improved to 33.12%, reflecting effective cost management and pricing strategies [37][39] Group 8: Company Analysis - Jianghe Group (江河集团) - Jianghe Group achieved a revenue of 21.845 billion yuan in 2025, a decrease of 2.50% year-on-year, while net profit was 610 million yuan, down 4.31% [42][43] - The company reported strong growth in overseas orders, with a 30% increase in new overseas contracts [42][43] - The gross margin improved to 17.24%, despite an increase in expenses due to currency fluctuations [42][43]

Investment Rating - The report assigns an "Accumulate" rating to the company, Hu Shang Ayi (02589.HK) [6]. Core Insights - The core logic for Hu Shang Ayi includes a diversified brand matrix covering different categories and price ranges, allowing the company to fully enjoy growth dividends across various segments. Additionally, the company focuses on deepening its presence in lower-tier markets and small store formats, which provides a differentiated competitive advantage. Revenue projections for 2025, 2026, and 2027 are estimated at 4.197 billion, 4.894 billion, and 5.790 billion yuan, respectively, with net profits of 493 million, 556 million, and 667 million yuan. The current stock price corresponds to a PE ratio of 15X, 13X, and 11X for the years 2025, 2026, and 2027, respectively, indicating a clear growth potential as the tea waterfall growth momentum is steadily released [1][16][17]. Summary by Sections 1. Industry Overview - The tea beverage industry is characterized as a high-quality track with sustained expansion driven by supply and demand. Brands with comprehensive capabilities are expected to gain advantages and maintain their leading positions in their respective price segments. The higher the price range, the more diverse the brands that can meet segmented consumer demands [2][48]. 2. Competitive Advantages - Hu Shang Ayi plans to launch 65 new products in 2024, maintaining an industry-leading frequency of new product introductions across tea and coffee categories priced between 2-23 yuan. By the first half of 2025, the total number of stores is expected to reach 9,436, reflecting an 11.84% year-on-year increase, with a CAGR of 34.44% from 2021 to 2024. The company has established a robust supply chain network consisting of 13 major logistics bases, 4 equipment warehouses, 7 fresh produce warehouses, and 14 front-line cold chain warehouses. Digitalization enhances business operations, while IP marketing strengthens brand recognition [3][21][22]. 3. Financial Performance - Revenue for 2023 is reported at 3.348 billion yuan, with a growth rate of 52.3%. The forecast for 2025 indicates a revenue of 4.197 billion yuan, representing a 27.8% increase. The net profit for 2023 is 388 million yuan, with a remarkable growth rate of 159.5%. The projected net profit for 2025 is 493 million yuan, reflecting a 49.8% increase. The company’s earnings per share (EPS) for 2025 is estimated at 4.68 yuan, with a PE ratio of 14.8 [4][28][32]. 4. Market Dynamics - The market perceives that the ready-to-drink tea segment has entered a phase of inventory pressure, making it challenging for mid-tier brands to increase their market share. However, the 10-20 yuan price range remains a continuously expanding segment, with significant potential for leading brands to increase their concentration. Hu Shang Ayi possesses advantages in northern and lower-tier markets, enabling it to maintain a strong competitive position [1][17][51].

Core Viewpoint - The new tea beverage industry is shifting from rapid expansion to a focus on optimizing single-store efficiency and exploring new growth avenues, with coffee becoming a key area of competition among brands [1][2][3]. Group 1: Company Developments - Mixue Ice City is actively expanding its product offerings, including the introduction of freshly brewed coffee machines in select stores and new cake products in flagship locations [1]. - The company is also developing a themed amusement park in Zhengzhou and has established a wholly-owned subsidiary for beer production [1]. Group 2: Industry Trends - Coffee has emerged as a critical battleground for tea brands, with most major tea companies, except for Bawang Chaji, now offering coffee products, often alongside baked goods [2]. - The introduction of coffee is seen as a way to capture different consumer demands throughout the day, as coffee and tea have different peak sales times [2]. - The industry consensus is that the focus has shifted from rapid expansion to enhancing single-store performance and diversifying product offerings to adapt to a more competitive market [3]. Group 3: Challenges and Risks - Despite the push for diversification, some attempts have failed, such as Tea Baidao's independent coffee brand, which closed shortly after opening, highlighting the challenges of brand positioning and operational efficiency [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Auntea Jenny (Shanghai) Industrial Co., Ltd. 滬上阿姨（上海）實業股份有限公司 （股 份 代 號：02589） 董事會會議通告 滬上阿姨（上 海）實業股份有限公司（「本公司」，連 同 其 附 屬 公 司「本集團」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 六 年 三 月 二 十 四 日（星 期 二）舉 行，藉 以（其 中 包 括）考慮及批准本集團截至二零二五年十二月三十一日止之年度業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有）及 處 理 其 他 事 務。 承董事會命 滬上阿姨（上 海）實業股份有限公司 董事會主席兼執行董事 單衛鈞先生 香 港，2026年3月12日 ...

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

公司名稱: 滬上阿姨（上海）實業股份有限公司 呈交日期: 2026年3月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02589 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 59,426,726 | RMB | | 1 | RMB | | 59,426,726 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 59,426,726 | RMB | | 1 | RMB | | 59,426,726 | | 2. 股份分類 | 普通 ...